ArticleBiological trace element research2025
Targets and Potential Mechanism of Chondroitin Sulfate A-selenium Nanoparticle on Kashin-Beck Disease Chondrocytes.
Article in Biological trace element research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kashin-Beck disease (KBD) is a chronic and deformable osteoarthropathy linked to low selenium. Limited cartilage regeneration poses challenges for its treatment. Previous studies have found that chondroitin sulfate A-selenium nanoparticle (CSA-SeNP) protects chondrocytes. This study used label-free LC-MS/MS quantitative proteomics to identify differentially expressed proteins and pathways in KBD chondrocytes post-CSA-SeNP treatment. Western blot (WB) was used to verify the key differential proteins, and transmission electron microscopy (TEM) was used to observe the ultrastructure of chondrocytes. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis revealed proteins mainly involved in RNA processing, translation, peptide biosynthesis, gene expression, rRNA metabolism, and ribonucleoprotein complex biogenesis. Notably, 121 proteins were up-regulated, 27 down-regulated, and 117 specifically expressed in the CSA-SeNP group. Enriched KEGG pathways included ribosome biogenesis, mRNA surveillance, endoplasmic reticulum protein processing, and endocytosis. Proteins related to autophagy, ER stress, cell homeostasis, protein processing and transport, including PELO, WES1, PLAA, RRBP1, ARC1B, ARFGAP2, and SH3KBP1, were significantly up-regulated in the CSA-SeNP group. In conclusion, our results demonstrated that CSA-SeNP may exert protective effects on chondrocytes in adult patients with KBD mainly through the regulation of target proteins and pathways related to ribosome biogenesis, mRNA surveillance, endoplasmic reticulum protein processing, endocytosis, autophagy, ER stress, and cell homeostasis. Further studies with larger sample size and in vivo to identify, screen and verify the regulatory effects of target proteins and pathways may provide more information for elucidating the mechanism of CSA-SeNP in the treatment of KBD.
Indexed as
Identifiers
40138104What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.